CLINICAL TRIALS PROFILE FOR ESTRADIOL; PROGESTERONE

505(b)(2) Clinical Trials for estradiol; progesterone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT05899010 ↗	MIcronized PROgesterone in Frozen Embryo Transfer Cycles	Not yet recruiting	Fundación Santiago Dexeus Font	Phase 3	2023-06-01	This randomized trial was designed as non-inferiority trial aiming to compare ongoing pregnancy rates following LPS with 600 mg/day vs 800 mg/day vaginal VMP. All patients will undergo an artificial cycle frozen embryo transfer (AC-FET) with transdermal estradiol 6mg/day Patients undergoing an artificial cycle FET will start estrogen priming with transdermal estradiol 6mg/day (Estrogel®) on cycle D1-D3. Following 10-12 days of estrogen priming, patients will be randomized to luteal phase support with a standard formulation (200mg tid, Utrogestan®) or a new formulation (400mg bid) VMP. All patients will undergo a serum P measurement on the day before embryo transfer (ET). Patients with P

All Clinical Trials for estradiol; progesterone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000897 ↗	A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00001259 ↗	A Treatment Study for Premenstrual Syndrome (PMS)	Completed	National Institute of Mental Health (NIMH)	Phase 1	1992-08-11	This study examines the effects of estrogen and progesterone on mood, the stress response, and brain function and behavior in women with premenstrual syndrome. Previously this study has demonstrated leuprolide acetate (Lupron (Registered Trademark)) to be an effective treatment for PMS. The current purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in women with PMS. PMS is a condition characterized by changes in mood and behavior that occur during the second phase of the normal menstrual cycle (luteal phase). This study will investigate possible hormonal causes of PMS by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. The results of these hormonal studies will be compared between women with PMS and healthy volunteers without PMS (see also protocol 92-M-0174). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
NCT00001322 ↗	The Effects of Reproductive Hormones on Mood and Behavior	Completed	National Institute of Mental Health (NIMH)	N/A	1994-06-09	This study evaluates the effects of estrogen and progesterone on mood, the stress response, and brain function in healthy women. The purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in healthy volunteer women without PMS. This study will investigate effects of reproductive hormones by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. Tests (such as brain imaging or stress testing, etc.) will be performed during the different hormonal conditions (low estrogen and progesterone, progesterone add-back, estrogen add-back). The results of these studies will be compared between women without PMS and women with PMS (see also protocol 90-M-0088). At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
NCT00001481 ↗	The Role of Hormones in Postpartum Mood Disorders	Recruiting	National Institute of Mental Health (NIMH)	Phase 2	1996-04-26	Determine whether postpartum depression is triggered by the abrupt withdrawal of estrogen and progesterone. The appearance of mood and behavioral symptoms during pregnancy and the postpartum period has been extensively reported. While there has been much speculation about possible biologically based etiologies for postpartum disorders (PPD), none has ever been confirmed. Preliminary results from two related studies (protocols 90-M-0088, 92-M-0174) provide evidence that women with menstrual cycle related mood disorder, but not controls, experience mood disturbances during exogenous replacement of physiologic levels of gonadal steroids. The present protocol is designed to create a "scaled-down" hormonal milieu of pregnancy and the puerperium in order to determine whether women who have had a previous episode of postpartum major effective episode will experience differential mood and behavioral effects compared with controls and to determine whether it is the abrupt withdrawal of gonadal steroids or the prolonged exposure to gonadal steroids that is associated with mood symptoms. Supraphysiologic plasma levels of gonadal steroids will be established, maintained, and then rapidly reduced, simulating the hormonal events that occur during pregnancy and parturition. This will be accomplished by administering estradiol and progesterone to women who are pretreated with a gonadotropin releasing hormone (GnRH) agonist (Lupron). After eight weeks, administration of gonadal steroids will be stopped in one group of patients and controls, and a sudden decline in the plasma hormone levels will be precipitated. Another group will be maintained on supraphysiologic levels of estrogen and progesterone for an additional month. Outcome measures will include mood, behavioral and hormonal parameters (a separate protocol done in collaboration with NICHD).
NCT00005108 ↗	Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	2000-04-01	This study will determine the effects of hormone replacement therapy (estrogen alone or estrogen and progesterone) on the walls of arteries in postmenopausal women. Inflammation and stiffness of artery walls are two risk factors for atherosclerosis-deposits of fatty substances (plaques) that can block the vessel, causing a heart attack or stroke. Estrogen raises the levels of certain substances in the blood that cause vessel inflammation and lowers the levels of others. This study will measure the net effects of estrogen on artery wall inflammation and stiffness. Postmenopausal women in good health may participate in this study. Volunteers will be screened for eligibility with a complete medical history, heart examination, and blood tests. Participants will be randomly assigned to receive either: 1) hormone therapy (estradiol 2 mg daily alone for women who have had a hysterectomy or estradiol plus micronized progesterone 200 mg daily for women with an intact uterus); or 2) placebo (look-alike pills that contain no active drug). Women in both groups will take pills for 3 months, then no pills for 1 month, and then will crossover to the alternate therapy for 3 months (i.e., those in the original placebo group will take hormones, and those in the hormone group will take placebo). At the end of each 3-month treatment period, participants will undergo the following procedures to assess blood vessel inflammation and stiffness: 1. Blood tests - 60 cc (about 2 ounces) of blood will be drawn to measure levels of hormones, cholesterol, and substances in the blood that indicate inflammation of the vessels. 2. Ultrasonography - an ultrasound probe will be applied gently on the neck to image the right and left carotid arteries (arteries in the neck that lead to the brain). During the procedure, the heart's electrical activity will also be monitored with an electrocardiogram and a blood pressure cuff will be wrapped around the arm to obtain blood pressure measurements every 5 minutes. 3. Magnetic resonance imaging (MRI) - Images of the carotid arteries are taken while the volunteer lies on a table in a narrow cylinder containing a magnetic field. A padded sensor called an MRI coil is placed over the neck and earplugs are placed in the ears to muffle the loud noise of the machine during scanning. During the second half of the exam, gadolinium is injected through a catheter (thin, flexible tube) inserted into a vein. Gadolinium is a contrast agent that is used to brighten the scan images. Information from this study will increase knowledge about the effects of estrogen on vessel wall inflammation. As such, it may be used in the future to help guide decisions about chronic hormone replacement therapy in postmenopausal women.

Clinical Trial Conditions for estradiol; progesterone

Condition Name

Condition Name for estradiol; progesterone
Intervention	Trials
Infertility	59
Menopause	20
Contraception	13
Breast Cancer	12

Condition MeSH

Condition MeSH for estradiol; progesterone
Intervention	Trials
Infertility	75
Breast Neoplasms	27
Polycystic Ovary Syndrome	15
Infertility, Female	10

Clinical Trial Locations for estradiol; progesterone

Trials by Country

Trials by Country for estradiol; progesterone
Location	Trials
United States	230
Egypt	35
Brazil	9
Spain	7
Canada	7

Trials by US State

Trials by US State for estradiol; progesterone
Location	Trials
California	18
Virginia	17
Illinois	17
North Carolina	14
New York	13

Clinical Trial Progress for estradiol; progesterone

Clinical Trial Phase

Clinical Trial Phase for estradiol; progesterone
Clinical Trial Phase	Trials
PHASE4	7
PHASE3	5
PHASE2	4

Clinical Trial Status

Clinical Trial Status for estradiol; progesterone
Clinical Trial Phase	Trials
Completed	122
Recruiting	57
Unknown status	34

Clinical Trial Sponsors for estradiol; progesterone

Sponsor Name

Sponsor Name for estradiol; progesterone
Sponsor	Trials
National Cancer Institute (NCI)	19
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	16
National Institute of Mental Health (NIMH)	12

Sponsor Type

Sponsor Type for estradiol; progesterone
Sponsor	Trials
Other	340
NIH	66
Industry	53

Estradiol + Progesterone Clinical Trials Update, Market Analysis and Forecast for Combined Hormone Therapy (HRT)

Last updated: July 28, 2026

Combined estradiol and progesterone products sit in a mature hormonal replacement therapy (HRT) market with a well-defined safety framework and recurring regulatory scrutiny around endometrial protection. In late-stage development, the practical differentiator has shifted toward dosing convenience (device and regimen), pharmacokinetic consistency, and risk management for vasomotor symptoms and bleeding outcomes rather than new drug targets. Commercially, growth is driven by aging demographics and preference for transdermal or lower-dose regimens, tempered by generics in estrogen-only segments and persistent class-level payer pressure.

What clinical trials are ongoing for estradiol plus progesterone (HRT) and when do key results read out?

Answer (featured snippet): Current late-stage readouts in estradiol-progesterone combinations depend on the specific branded product, formulation platform (oral vs transdermal vs implant), and whether “progesterone” is natural progesterone (micronized progesterone) or a synthetic progestin substitute. Without a product identifier tied to a specific combination (eg, estradiol valerate + dydrogesterone vs estradiol hemihydrate + micronized progesterone vs transdermal estradiol + oral progesterone), a complete and accurate trials-and-timeline update cannot be produced.

What product form factors dominate estradiol + progesterone clinical development?

• Transdermal estradiol with oral micronized progesterone: targets improved tolerability and steadier estradiol exposure; trials focus on bleeding patterns, adherence, and endometrial safety.
• Oral estradiol with oral progesterone: emphasizes regimen adherence and drug-drug interaction stability.
• Fixed-dose “duo” products vs separate prescribing: fixed-dose combinations reduce titration complexity and may improve persistence metrics.

What endpoints typically drive trial readouts in estradiol-progesterone programs?

• Vasomotor symptom reduction: change from baseline in hot flash frequency/severity.
• Endometrial safety: incidence of hyperplasia or abnormal bleeding requiring investigation.
• Bleeding profile: rates of unscheduled bleeding, spotting, and discontinuation due to bleeding.
• PK/PD bridging: in formulation changes, exposure consistency can be the central regulator-facing endpoint.
• Adherence and persistence: especially for combination packs designed to reduce missed progestogen doses.

How do trial designs typically differ by progestogen type?

• Natural progesterone (micronized progesterone) programs often emphasize endometrial outcomes and bleeding patterns versus progestins.
• Synthetic progestins introduce different safety and efficacy signaling expectations, so trials may not be directly comparable across product classes.

How big is the market for estradiol/progesterone therapy and what segments drive growth?

Answer (featured snippet): Growth is supported by postmenopausal population expansion and migration from older dosing regimens to transdermal estradiol-based therapy. The combined estradiol-progestogen segment is also shaped by payer edits and guideline-based restrictions related to indication, duration, and patient risk profile.

Market structure by regimen and route

• Route
  • Transdermal estradiol combinations generally capture a premium segment tied to tolerability and reduced hepatic first-pass effect expectations.
  • Oral regimens carry higher sensitivity to GI tolerance and thrombotic risk perception, impacting payer coverage.
• Regimen type
  • Continuous-combined regimens favor fewer withdrawal bleeds and improved predictability, which can boost persistence.
  • Cyclic/sequential regimens remain relevant for certain physician preferences and patient symptom-response patterns.

Segment drivers

• Demographics: expanding older female population increases addressable patient pool.
• Guideline adherence and risk stratification: safety labeling and monitoring requirements influence prescribing.
• Generic competition: estrogen-only categories face more rapid generic entry dynamics, while combination products and specific progestogen formats often retain brand defensibility longer.

What is the forecast for estradiol + progesterone sales to 2030, and what scenarios matter?

Answer (featured snippet): A defensible forecast requires the specific marketed product(s), geography, and whether “progesterone” refers to natural progesterone or includes progestin classes. Without product-level and geography-level identification, a complete and accurate 2030 projection cannot be produced.

Key variables that drive model outcomes

• Patent and exclusivity clocks: fixed-dose combinations and device-linked delivery systems can delay generic substitution.
• Payer utilization management: step therapy and formulary restrictions can compress net pricing.
• Safety perceptions and label evolution: class-level risk communications can shift market share across progestogen types and routes.
• Competitive entry: new transdermal platforms or new fixed-dose combinations can change channel dynamics.

Scenario framework used by market models

• Base case: continuation of guideline-driven prescribing with gradual migration toward transdermal and continuous combined regimens.
• Downside case: expanded utilization controls and stronger bleeding-safety concerns reduce persistence and increase discontinuation.
• Upside case: improved adherence devices, better-real-world tolerability, and stable pricing with moderate volume capture.

How does estradiol + progesterone compare with estradiol-only therapy in safety and payer dynamics?

Answer (featured snippet): Estradiol-only is generally confined to women without a uterus, while combined therapy addresses endometrial protection needs. Payer dynamics often reward the presence of endometrial protection and predictable bleeding profiles, but all estrogen-based therapy remains exposed to class-level thrombotic and cardiovascular risk considerations.

What matters for clinical and commercial differentiation?

• Endometrial protection coverage: consistent progestogen delivery reduces the clinical rationale for off-label use.
• Bleeding outcomes: unscheduled bleeding drives discontinuation and limits uptake in some regimens.
• Risk stratification: product positioning often reflects patient baseline risk categories.

Commercial implication

• Payers typically align coverage with guideline adherence and labeled indications. Combination products can be favored when they reduce regimen errors, especially where progestogen omission risk is high.

Which companies lead estradiol + progesterone therapy, and what are their competitive strategies?

Answer (featured snippet): Market leadership typically concentrates among manufacturers with established HRT portfolios and fixed-dose combination or device-supported delivery. Competitive strategies center on route migration (transdermal), regimen simplification, patient support programs, and lifecycle management through reformulations.

Common competitive moves

• Lifecycle expansion: new dose strengths, device improvements, or regimen refinements.
• Evidence packages: real-world bleeding and persistence data supporting formulary negotiations.
• Channel strategy: switching strategies within mail-order and large provider systems.

What is the Orange Book status for marketed estradiol/progesterone combination products?

Answer (featured snippet): Orange Book status is product-specific and requires a defined set of NDA/BLA identifiers tied to a particular estradiol-progesterone combination. Without exact product identity, an accurate Orange Book mapping cannot be generated.

What Orange Book items usually matter most in HRT combinations?

• Drug substance/active ingredient protection
• Drug product formulation protection
• Method of treatment protection (less common than formulation for HRT lifecycle management, but can be relevant)
• Combinatorial coverage for fixed-dose or specific delivery systems

What patent and litigation risks affect generic or biosimilar entry for estradiol + progesterone combinations?

Answer (featured snippet): Generic entry risk depends on whether the relevant product is protected as a fixed-dose combination, has formulation-specific patents, and whether Paragraph IV certifications are filed against the Orange Book-listed patents. A complete litigation and risk map requires product-specific patent and Orange Book listings.

Where litigation tends to cluster

• Formulation and dosage form patents
• Device-related delivery system claims
• Indication and dosing regimen claims where present in the Orange Book

What generic entry risks exist for estradiol + progesterone, and when do exclusivity barriers fall?

Answer (featured snippet): Entry timing hinges on the last-to-expire patent and the remaining exclusivity period for each specific marketed NDA. Without the specific product and its Orange Book patent list, generic entry windows cannot be stated.

Practical timing drivers

• Last patent expiration date
• Pediatric exclusivity or other statutory extensions
• Oral vs transdermal product-specific life cycle
• Switchability: whether the combination is substitutable at the pharmacy and payer level

What FDA status matters for estradiol + progesterone products (label indications and pathways)?

Answer (featured snippet): Most estradiol-progestogen products are approved under NDA pathways for specific regimens and dosing schedules. Whether a product is “brand” or “authorized generic” affects market access. Accurate FDA status requires product-level NDA identifiers.

Label elements that shape market access

• Indication scope (vasomotor symptoms, prevention of postmenopausal osteoporosis where applicable)
• Population (uterus present/absent, age, time since menopause)
• Regimen instructions (cyclic vs continuous combined)
• Safety communications (thrombotic risk, monitoring guidance)

Key Takeaways

• Estradiol + progesterone HRT remains a mature market with competitive differentiation driven by regimen convenience, transdermal preference, and bleeding/endometrial safety outcomes rather than new mechanistic classes.
• Clinical trials primarily target vasomotor symptom relief, bleeding profiles, endometrial safety, and PK consistency for formulation and regimen upgrades.
• Any credible clinical-trials update, patent/exclusivity timeline, and 2030 sales forecast must be anchored to specific combination products (NDA/BLA) and defined geography. Without that anchor, product-accurate timelines and Orange Book/patent risk mapping cannot be produced.

FAQs

1. Which estradiol plus progesterone combination products have the longest patent life in the US?
2. Are transdermal estradiol plus oral progesterone regimens associated with lower discontinuation due to bleeding than oral regimens?
3. How do payer prior authorizations typically differentiate continuous-combined versus cyclic HRT regimens?
4. What endpoints does the FDA prioritize in postmenopausal hormone therapy trials for endometrial safety?
5. What are the most common generic substitution barriers for fixed-dose estradiol-progestogen combination products?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. Drug Trials Snapshots (various studies for postmenopausal hormone therapy). FDA.
3. National Institutes of Health / peer-reviewed sources on postmenopausal hormone therapy endpoints and endometrial safety considerations.